DOD Biotech Public Company Limited (DOD) has announced its 3Q21 consolidated financial statement through the Stock Exchange of Thailand as follows;
In 3Q21, DOD had a profit of THB 22.00 Million, which decreased 68.33%, compared with the same period of the last year, which mainly came from the decrease in revenue. Revenue from sales was THB 184.25 Million which decreased by THB 106.03 Million or 36.53% compared with the same period of last year due to the outbreak of the coronavirus disease 2019 (COVID-19).
The operating profit was THB 41.32 Million which decreased by THB 45.70 Million or 52.52% compared with the same period of the last year due to the outbreak of the coronavirus disease 2019 (COVID-19).
